At a glance
ClinicalIndex Comparison RecordN/ACompleted· 254 enrolled
Drug / intervention
No interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment
In Brief
An observational study evaluating No intervention for Multiple Myeloma. Completed, enrolled 254 participants across 75 sites in 10 countries.
Detailed Summary
The purpose of this study is to assess the safety and clinical response including overall response rate (ORR) of real-life standard-of-care (SOC) treatments under routine clinical practice, over a 24-month period, in patients with relapsed/refractory multiple myeloma (RRMM).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesBelgium, France, Germany, Italy, Netherlands, Poland, Russia, Spain, United Kingdom, United States
CollaboratorsLegend Biotech
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartAug 2019
Primary CompletionOct 2022
TodayJul 2026
First PostedJul 29, 2019
Enrollment StartAug 2, 2019
Primary CompletionOct 27, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.9 years ago
Interventions
No interventionother
No intervention will be administered as a part of this study.